Trial Profile
A Phase I/IIa (Phase 1/Phase 2a), Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Apr 2024
Price :
$35
*
At a glance
- Drugs RGX 314 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors REGENXBIO
- 28 Mar 2024 According to a REGENXBIO Media Release, two year data of this trial were published in The Lancet.
- 28 Mar 2024 Results presented in a REGENXBIO Media Release.
- 27 Mar 2024 Results assessing the safety and efficacy of subretinal injection of RGX-314 in patients with neovascular age-related macular degeneration, published in the Lancet.